MenüForum-NavigationForumMitgliederAnmeldenRegistrierenForum-Breadcrumbs - Du bist hier:ForumFlohmarkt: Allgemeines0jzhyaAntwortenAntworten: 0jzhya <blockquote><div class="quotetitle">Zitat von Gast am 31. März 2026, 11:01 Uhr</div>Hello. This post was created with XRumer 23 StrongAI. Good luck :) https://tsn.ua/ru [url=https://www.nba.com/ ]Basketball1[/url] variant4 [url=]Zoya Demidenko[/url]: Scholar in Cancer Science [url=]Zoya Demidenko[/url] is a notable researcher connected with the Division of Cell Stress Biology at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, establishing a robust background in clinical research. Her scholarly contributions spans several key domains, including the PI3K/AKT/mTOR molecular pathway, cellular cycle control, biological aging, and tumor biology. To date, she has authored more than 46 scientific publications, which have garnered upwards of 4,100 citations — a reflection to the impact of her work. Among her key contributions involves explaining the processes of cell aging. Her research showed that when the cellular division cycle is arrested while cellular growth persists, cells undergo senescence. Crucially, [url=]Zoya Demidenko[/url] demonstrated that this transition can be controlled with drugs using compounds such as mTOR inhibitors. [url=]Zoya Demidenko[/url] has additionally brought substantially to oncological therapy research, especially in the domain of cyclotherapy — a method intended to shielding normal cells from anticancer drugs whilst leaving cancer cells vulnerable. This approach carries major potential for diminishing the adverse effects of oncological therapy. Throughout her scientific life, Demidenko has worked with top scientists worldwide, such as Dr. Mikhail Blagosklonny. Her publications appears in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.</blockquote><br> Abbrechen
